Beam Therapeutics (BEAM) Non Operating Income (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Non Operating Income data on file, last reported at $12.9 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 17.72% year-over-year to $12.9 million in Q1 2026; TTM through Mar 2026 was $306.6 million, a 591.15% increase from a year earlier, with the FY2025 full-year figure at $303.7 million, up 681.43% from the prior year.
• Non Operating Income for Q1 2026 stood at $12.9 million, down from $261.7 million in the prior quarter.
• Over the last five years, Non Operating Income for BEAM reached as high as $261.7 million in Q4 2025 and fell as low as $2.5 million in Q1 2023.
• Historically, Non Operating Income has averaged $28.2 million across 5 years, with a median of $11.3 million in 2023.
• Across the five-year window, Non Operating Income jumped 4322.08% in 2022 and plunged 78.11% in 2023, its largest moves.
• Year by year, Non Operating Income stood at $51.6 million in 2022, then plunged by 78.11% to $11.3 million in 2023, then declined by 14.35% to $9.7 million in 2024, then soared by 2603.11% to $261.7 million in 2025, then sank by 95.07% to $12.9 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $12.9 million in Q1 2026, $261.7 million in Q4 2025, and $14.1 million in Q3 2025.